Pharmacology Commons^™

Ascorbic Acid-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles Incorporated Into A Polyacrylic Acid Gel As A Promising Tool For Site-Specific Oral Cancer Therapy, Nurul Ain Mohammad Hamdi, Ahmad Fahmi Harun Ismail, Muhammad Salahuddin, Widya Lestari

The Thai Journal of Pharmaceutical Sciences

Background: Chemotherapy is commonly used in oral cancer therapy, especially as the disease advances. However, it is associated with terrible adverse effects and the occurrence of chemoresistance which causes treatment failure. Thus, discovering a new potential anticancer agent and developing a safe, effective, and non-invasive drug delivery are necessary. Objective: The objective of the current study is to develop ascorbic acid-loaded poly(lactic-co-glycolic) acid (AA-PLGA) nanoparticles incorporated into polyacrylic acid gel intended to treat oral cancer. Materials and methods: Double emulsion solvent evaporation method was used to fabricate AA-PLGA nanoparticles. Optimization was carried out in the primary emulsion based on multilevel …

Formulation, Characterization, And Pharmacokinetic Study Of Methoteraxate-Quercetin Loaded Nanoparticles, Gyanesh Kumar Sahu, Harish Sharma, Swarnali Das Paul, Ajazuddin, Chanchal Deep Kaur

The Thai Journal of Pharmaceutical Sciences

Objectives: Methotrexate (MTX) is a biopharmaceutics classification system Class IV drug having potential cytotoxic action against cancer cells. However, short half-life and poor bioavailability have limited its application. The object of this work was to entrap MTX and an herbal bioenhancer in a nanoparticle system to improve its bioavailability. Methods: We prepared the nanoparticles (NPs) by emulsion solvent evaporation method with Eudragit RLPO (ERLPO) polymer. Results: The result revealed good in vitro properties with 110 to 228 nm particle size range. The percentage of drugs released from all the batches in 72 h was within the range of 82.71 to …

Pharmacokinetic Study Of Novel Anthraquinone Analogues, Yuhan Guo

Electronic Theses and Dissertations

Small molecules functioning as negative regulators of MDM2 have been considered as promising anti-cancer agents. A series of novel anthraquinone (AQ) analogues upregulate p53, a well-known tumor suppressor, by inactivating its antagonist protein MDM2. The novel AQ compounds synthesized through the modifications on the rhein scaffold were reported to have successfully arrested tumor growth. To have a better understanding of their underlying metabolism in vivo, pharmacokinetic (PK) studies were performed for the AQ compounds. A selective, accurate and reproducible assay methodology for PK study was set up for each AQ compound. The stabilities of AQ compounds were then evaluated …

Biological Activities Of Fusarochromanone: A Potent Anti-Cancer Agent, Elahe Mahdavian, Phillip Palyok, Steven Adelmund, Tara Williams-Hart, Brian D. Furmanski, Yoon-Jee Kim, Ying Gu, Mansoureh Barzegar, Yang Wu, Kaustubh N. Bhinge, Gopi K. Kolluru, Quincy A. Quick, Yong-Yu Liu, Christopher G. Kevil, Brian A. Salvatore, Shile Huang, John L. Clifford

Biology Faculty Research

Background

Fusarochromanone (FC101) is a small molecule fungal metabolite with a host of interesting biological functions, including very potent anti-angiogenic and direct anti-cancer activity.

Results

Herein, we report that FC101 exhibits very potent in-vitro growth inhibitory effects (IC₅₀ ranging from 10nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive. FC101 induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT …